Expert opinion on drug metabolism & toxicology · 2008
An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Crouse John R
Аннотация
BACKGROUND: The HMG Co-A reductase inhibitors (statins) are the most efficacious agents for lowering cholesterol. Statins reduce clinical cardiovascular events and are generally well tolerated.
OBJECTIVE: To review the efficacy and safety of rosuvastatin, the newest and most potent of the approved statins.
METHODS: A comprehensive (PubMed) search was performed to identify relevant publications up to May 2007.
RESULTS/CONCLUSIONS: Rosuvastatin reduces LDL cholesterol (LDL-C) by up to 50%, and by 70% when combined with ezetimibe. Rosuvastatin also reduces plasma triglycerides and increases HDL-C, and slows atherosclerosis progression in coronary and carotid arteries in both low-risk and high-risk individuals. Tolerability is comparable with other statins. Clinical trials to evaluate cardiovascular outcomes have recently been published (CORONA) or are underway.
OBJECTIVE: To review the efficacy and safety of rosuvastatin, the newest and most potent of the approved statins.
METHODS: A comprehensive (PubMed) search was performed to identify relevant publications up to May 2007.
RESULTS/CONCLUSIONS: Rosuvastatin reduces LDL cholesterol (LDL-C) by up to 50%, and by 70% when combined with ezetimibe. Rosuvastatin also reduces plasma triglycerides and increases HDL-C, and slows atherosclerosis progression in coronary and carotid arteries in both low-risk and high-risk individuals. Tolerability is comparable with other statins. Clinical trials to evaluate cardiovascular outcomes have recently been published (CORONA) or are underway.